Key Takeaways J&J's oncology sales rose 20.6% to $18.52B, fueled by Darzalex, Erleada and new cancer drugs.ImmunityBio's Anktiva gained U.S. approval for NMIBC, with $74.7M in 2025 sales.Foghorn Therapeutics is advancing FHD-909 for SMARCA4-mutant cancers.An updated edition of the October 28, 2025, article.The global oncology market is entering a period of significant evolution, supported by rising cancer incidence and rapid scientific advancement. The American Cancer Society estimates that the United State ...

*Real-time prices by Nasdaq Last Sale. Real-time quote and/or trade prices are not sourced from all markets. Ownership data provided by LSEG and Estimate data provided by FactSet. IBD, IBD Digital, IBD Live, IBD Weekly, Investor's Business Daily, Leaderboard, MarketDiem, MarketSurge and other marks are trademarks owned by Investor's Business Daily, LLC. ©2025 Investor's Business Daily, LLC. All Rights Reserved. About Us Reviews Site Map Your Ad Choices Advertising Contact us IBD Stock Charts IBD Stock Check ...

(Bloomberg) -- UBS Group AG is set to begin its latest wave of job cuts in mid-January, according to people familiar with the matter. That step will be followed by another round later in 2026 as UBS intends to switch off computer systems it acquired when it took over its former competitor in 2023, the people said, asking not to be named discussing internal matters.UBS is entering the final year of its historic integration of Credit Suisse, which it bought in an emergency government-brokered deal in 2023. Th ...

You can find original article here WealthManagement. Subscribe to our free daily WealthManagement newsletters. (Bloomberg) -- UBS Group AG is set to begin its latest wave of job cuts in mid-January, according to people familiar with the matter.  That step will be followed by another round later in 2026 as UBS intends to switch off computer systems it acquired when it took over its former competitor in 2023, the people said, asking not to be named discussing internal matters. UBS is entering the fi ...

Core Insights - Micron's stock surged significantly following a strong earnings report, driven by tighter supply in the memory market [1] - The company’s advanced memory production for AI is sold out through 2026, with memory pricing increasing by 20% quarter-over-quarter and storage chips rising in the mid-teens [2] - Micron's CFO anticipates continued improvement in margins and performance through fiscal 2026, although pricing increases are expected to slow after February [2] Industry Impact - The rising memory costs are affecting major hyperscalers like Amazon, Microsoft, and Google, which need these chips for AI data centers, leading to higher operational costs [4] - Server manufacturers such as Dell, Lenovo, and HPE are passing on increased costs to consumers, with HPE raising server prices by 15% and Dell expected to increase prices by 15-20% [4][5] - Broadcom is also experiencing margin compression due to rising memory costs, contributing to an 11% decline in their stock post-earnings [5]

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. ( RXRX ) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4.5Edmund Ing ...

The first fresh inflation reading since the government shutdown showed prices unexpectedly eased in November, though the report may not immediately change the Fed’s outlook because of potential distortions in the data. “This looks like positive news overall, but the lack of detail and the absence of data collection during the shutdown introduce a degree of skepticism that’s hard to ignore,” said Olu Sonola, head of US economic research for Fitch Ratings. “We’ll need to wait until next month for a clearer ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - Recursion Pharmaceuticals, Inc. (RXRX) has seen a rise in share price, increasing from approximately $4.5 in early October, indicating positive market sentiment towards the company [1]. Company Overview - Recursion Pharmaceuticals is categorized as a TechBio company, focusing on biotechnology and healthcare sectors [1]. - The company is under the coverage of a biotech consultant with over five years of experience in the industry, who has analyzed more than 1,000 companies [1]. Investment Group Insights - The Haggerston BioHealth investing group provides resources for both novice and experienced biotech investors, including catalysts to monitor, buy and sell ratings, and detailed financial forecasts for major pharmaceutical companies [1]. - The group also offers integrated financial statements, discounted cash flow analysis, and market-by-market analysis, which are essential for informed investment decisions in the biotech sector [1].

Analyst’s Disclosure:I/we have a beneficial long position in the shares of ASML, SBGSY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.Past performance is no guarantee of future results. All opinions and data included in this commentary are as of the publication date and are subject to change. The opini ...